Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AdnaGen AG
AdnaGen AG and OncoVista Innovative Therapies Inc., Announce the Issuance in the U.S. of a Key Patent Related to Technology for the Detection and Analysis of Circulating Tumor Cells
April 10th, 2009
AdnaGen AG, a molecular diagnostics company, and subsidiary of OncoVista Inc., (OTCBB:OVIT.OB), focused on the detection and molecular analysis of tumor cells from the blood of cancer patients has been issued a core-patent by the United States Patent and Trademark Office. United States Patent 7,507,528 issued Mar 24, 2009, and titled “Method and Diagnosis Kit for Selecting and or Qualitative and/or Quantitative Detection of Cells”, claims broad methods for the identification and molecular analysis of rare cells, particularly circulating tumor cells, in the presence of a large excess of unrelated cells. A corresponding European Patent EP 1 409 727 with a priority date of...
Source: Health Business Week (2009-04-10)
|
